Clinical trials: Renal Disorder
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Kidney Disease, Diabetes
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress…
- Trial name
- NCT01350388
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Cancer of Kidney, Kidney Cancer
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
- Conditions
- Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney
- Trial name
- NCT00199888
- Testing
- 124-Iodine-cG250 (124I-cG250)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ludwig Institute for Cancer Research
BK Virus Infection
Ciprofloxacin for Prevention of BK Infection
BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower…
- Trial name
- NCT01789203
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Methodist Hospital Research Institute
Renal Cell Cancer Metastatic, Kidney Cancer Metastatic
Interleukin-2 in Metastatic Kidney Cancer
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.
- Trial name
- NCT01702909
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Western Regional Medical Center
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Thrombotic Microangiopathies
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
- Trial name
- NCT02222545
- Testing
- OMS721
- Where
- 24 sites in United States, Belgium and 10 more
- Volunteers
- 58 people
- Sponsor
- Omeros Corporation
End Stage Renal Disease, AV Fistula
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Trial name
- NCT02363972
- Testing
- Ellipsys Vascular Access Catheter
- Where
- 5 sites in United States
- Volunteers
- 103 people
- Sponsor
- Medtronic Endovascular
IgA Nephropathy, Berger Disease
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- Trial name
- ORIGIN 3 (NCT04716231)
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Vera Therapeutics, Inc.
Carcinoma, Renal Cell
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy.
- Trial name
- NCT02560012
- Testing
- Sunitinib, Temsirolimus, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Atherosclerosis, Cardiovascular Diseases
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery Obstruction
- Trial name
- CORAL (NCT00081731)
- Testing
- Atacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
- Where
- United States
- Volunteers
- 947 people
- Sponsor
- Baim Institute for Clinical Research
Acute Kidney Injury, Dialysis Hypotension
Outpatient Recovery From Acute Kidney Injury Requiring Dialysis
There are currently no therapies to improve the chances of recovering enough kidney function to come off of dialysis after severe acute kidney injury.
- Trial name
- ORKID (NCT05158153)
- Testing
- ORKID Bundled Intervention, Furosemide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Kidney Failure, Graft vs Host Disease
A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients
This study evaluates two different immunosuppression drug regimens in patients with a recent kidney transplant. Patients initially received a regimen of Sirolimus, Tacrolimus and Prednisone and then randomized to discontinue…
- Trial name
- NCT00195429
- Testing
- Tacrolimus, Sirolimus, prednisone
- Where
- Brazil
- Volunteers
- 47 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois Chicago
Primary IgA Nephropathy
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal…
- Trial name
- Nefigard (NCT03643965)
- Testing
- Nefecon
- Where
- 142 sites in United States, Argentina and 17 more
- Volunteers
- 365 people
- Sponsor
- Calliditas Therapeutics AB
End Stage Renal Failure, Hemodialysis Access Failure
Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas
An arteriovenous (AV) fistula is essential for patients with kidney failure on dialysis. There is no clear data on the best method to create a new brachial basilic AV fistula (BBAVF), so the choice between a single procedure and…
- Conditions
- End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
- Trial name
- NCT04376567
- Testing
- One stage approach
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tze-Woei Tan
Kidney Calculi
ShockPulse-SE vs. Trilogy Trial: Comparing the Performance of Two Intracorporeal Lithotripters for Removal of Large Renal Calculi
The purpose of this study is to measure how well two different devices work to break up and remove kidney stones. We are comparing a newer device to an older one to see which one is faster at breaking up kidney stones.
- Trial name
- NCT03959683
- Testing
- Trilogy Lithotrite, The ShockPulse-SE Lithotripsy System
- Where
- 4 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Indiana University
ADPKD
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The proposed research will determine the effectiveness of blocking aldosterone for improving the health and function of arteries in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT01853553
- Testing
- Spironolactone, Sugar pill
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Colorado, Denver
Chronic Kidney Disease
Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)
The EPOCH-RRT study seeks to fill knowledge gaps by gaining more understanding of chronic kidney disease (CKD) patients' priorities; assessing the comparative benefits of hemodialysis (HD) versus peritoneal dialysis (PD), with…
- Trial name
- EPOCH-RRT (NCT01952600)
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- Arbor Research Collaborative for Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.